Dr. Anna Burke Named 2019 Healthcare Innovator of the Year

/

AzBusiness recognized Dr. Anna Burke as its 2019 Healthcare Innovator of the Year for her work in treating the behavioral and psychiatric disturbances that result from Alzheimer’s disease as well as her work building a community outreach program in the Phoenix area to teach people about brain health, Alzheimer’s, and clinical research. Dr. Burke is […]

Read more »

When It Comes to Alzheimer’s, Important Changes Are Coming for MA Beneficiaries

/

The majority of experts agree that because Alzheimer’s disease is significantly underdiagnosed and underreported, a large number of people may not know they have it.  We have both spoken at length about the importance of early detection and diagnosis to allow for earlier interventions and care planning along with a broad array of methods and […]

Read more »

Alzheimer’s Disease Trials: Where Do We Go From Here?

/

The Alzheimer’s disease space is not an easy one for pharma companies to navigate. In 2018 alone, Lundbeck, Takeda, Merck, Janssen, AstraZeneca, and Eli Lilly and Company all faced setbacks or poor trial results. In March 2019, we learned that Biogen and Eisai also terminated late-phase studies. Fortune magazine notes few spaces in the life […]

Read more »

In Year Three, GAP Trial Network Is Starting to Hum

/

Outside the daffodils and forsythia were blooming, but the group assembled in Nashville, Tennessee, hardly took notice. At the GAP-Net Site Optimization Conference, held February 27–March 1, representatives of 61 academic and private clinical trial sites had eyes and minds trained on efforts aiming to improve how Alzheimer’s disease clinical trials are done—and after years […]

Read more »

Addressing the GAPs in Alzheimer’s Trials, Treatment

/

The Global Alzheimer’s Platform (GAP) Foundation, an organization dedicated to improving Alzheimer’s clinical trials in the quest of a cure, has just wrapped the GAP-NET Site Optimization Conference in Nashville. The Feb. 27-March 1 meeting brought together approximately 150 representatives from its network of Alzheimer’s clinical research sites. The third annual GAP-NET conference attracted the […]

Read more »

Boosting Alzheimer’s trial participation via Medicare Advantage “memory fitness programs”

/

Clinical trials represent future hope for patients seeking better care, and there is no disease more in need of better care than Alzheimer’s disease. While death rates among most cancers, as well as heart disease, HIV-related illness, and other categories, have declined in the past decade, there has been no progress for Alzheimer’s disease. Better […]

Read more »

A Cure for Alzheimer’s is Not Possible Without You

/

There are many open, important clinical trials in Tennessee right now targeting Alzheimer’s disease and related conditions. It’s been 18 months since Nashville legend Glen Campbell died after a long battle with Alzheimer’s disease. Glen and his family bravely shared his heartbreaking journey in the hope of inspiring better care and research for the disease, […]

Read more »

Top Alzheimer’s Researchers Hope That Near-100 Dementia Drugs in Trials Are Moving Closer to a Breakthrough

/

Top Alzheimer’s Researchers Hope That Near-100 Dementia Drugs in Trials Are Moving Closer to a Breakthrough The search for a drug to treat Alzheimer’s disease, the most common form of dementia, has been marked by clinical trial failures. A new report from top researchers says the number of drugs advancing through clinical phase two and […]

Read more »

How a Raleigh Clinic is Helping Alzheimer’s Patients

/

Alzheimer’s clinical trial participants are getting a lift to their appointments at Raleigh Neurology Associates. The Global Alzheimer’s Platform Foundation, in partnership with Lyft, is providing transportation to participants in an Eli Lilly study testing a therapy to attack plaque in the brain characteristic of Alzheimer’s disease. Sean Walsh, director of clinical research at Raleigh Neurology Associates, says the new […]

Read more »

Can GAP double the number of patients in Alzheimer’s trials?

/

Curing diseases requires new drugs. Getting those new drugs approved by regulators requires data from successful clinical trials. Those trials depend on patients, and right now getting those patients is a challenge for many sponsor companies. According to research performed on recruitment, 85 percent of trials are delayed due to enrollment issues and more than […]

Read more »

Minority Participation in Clinical Trials can Help Everyone Fight Alzheimer’s

/

Growing up as an African-American in the South over 75 years ago, my family didn’t have the access to medical care we do today. One event from my childhood changed my life.  My mother went to the doctor’s office. She was quite ill and needed help. The doctor said she had to wait to be […]

Read more »

Patient Advocacy Groups Welcome 40% Increase in Alzheimer’s NIH Research Funds Authorized by Congress

/

The U.S. Congress last week authorized an additional 40 percent in funds for Alzheimer’s disease (AD) research, boosting the fiscal 2017 total by $400 million to nearly $1.4 billion as part of a $2 billion year-over-year increase for the National Institutes of Health (NIH). The final package won praise from the nonprofit Global Alzheimer’s Platform Foundation (GAP), […]

Read more »

Hope to Prevent Alzheimer’s? Grab the Olive Oil and Hop on a Treadmill

/

Ann Poehler’s strides quicken on the treadmill. Her feet pound. Her heart races from 150 to 160 beats per minute and more. A plastic tube jutting from the Prairie Village woman’s mouth feeds carbon dioxide levels to a computer here inside the University of Kansas Alzheimer’s Disease Center. The computer records every respiration while an exercise […]

Read more »

National Survey Finds that a Majority of Americans Would Consider Participating in an Alzheimer’s Clinical Trial

/

A recent online survey conducted by Harris Poll found that nearly 60% of Americans are definitely willing or willing to consider taking part in a clinical trial for Alzheimer’s. This promising statistic is good news for researchers; however, obtaining qualified trial participants has been one of the greatest challenges in getting clinical trials off the […]

Read more »
To top